Astrazeneca Pharma India Limited

BSE: 506820 NSE: ASTRAZEN
Astrazeneca Pharma India Limited - pharma in Bangalore, Karnataka, India. FY 2026 financials and compliance.
CIN L24231KA1979PLC003563 Incorporated 11 July 1979 ROC Bangalore HQ Bangalore, Karnataka, India
Active Listed - NSE: ASTRAZEN · BSE: 506820 Public Limited Company pharma
Data last updated
Revenue · FY 2026
₹2,275.58 Cr
▲ 32.59% YoY
EBITDA · FY 2026
₹290.52 Cr
▼ 1.38% YoY
Net profit · FY 2026
₹187.52 Cr
▲ 62.02% YoY
Authorised capital
₹5 Cr
Registered with MCA
Paid-up capital
₹5 Cr
Issued & subscribed
Open charges
None
Satisfied ₹62.5 Cr
Company age
47 yrs
Est. 1979
Employees · EPFO
935
Latest available

About Astrazeneca Pharma India Limited

Data last updated: 22 December 2025

Astrazeneca Pharma India Limited is a public limited company based in Bangalore, Karnataka, India, a subsidiary of Astrazeneca Pharmaceuticals Ab. It specialises in drug formulation and development, a part of the broader pharmaceuticals sector. Incorporated on 11 July 1979, the company has been in operation for over 47 years.

Registered with ROC Bangalore under CIN L24231KA1979PLC003563. Listed on BSE: 506820 and NSE: ASTRAZEN.

Capital: an authorised share capital of ₹5 Cr and a paid-up capital of ₹5 Cr. Formerly known as Astra Idl Limited. It is led by directors including Revathy Ashok and Hooi Bien Chuah.

Last AGM: 14 August 2025. Financial statements filed for year ended 31 March 2025. Office: Block N1 12Th Floor Manyata Embassy Business Park Rachenahalli Outer Ring Road, Bangalore, Karnataka, India – 560045.

As per the financials filed for FY 2025, the company reported a revenue of ₹1,756.92 Cr, a growth of 32% compared to the previous year.

The company has a workforce of approximately 935 employees as per the latest available data. It operates as a subsidiary of Astrazeneca Pharmaceuticals Ab.

As per MCA filings, the company has satisfied charges of ₹62.5 Cr on record.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website astrazeneca.in.

Company Details of Astrazeneca Pharma India Limited
CIN L24231KA1979PLC003563
Registration Number 003563
Incorporation Date 11 July 1979
ROC Bangalore
Listing Status Listed (BSE: 506820, NSE: ASTRAZEN)
Company Status Active
Date of Last AGM 14 August 2025
Date of Balance Sheet 31 March 2025
Parent Company Astrazeneca Pharmaceuticals Ab
Compliance Status Active Compliant
Key People
Praveen Rao Akkinepally Managing Director Bhavana Agrawal Cfo Revathy Ashok Director
Contact Details
  • Email
    *****@*****.com
  • Telephone
    +91-****-******
  • Website
    astrazeneca.in
  • Social Media
  • Registered Address
    Block N1 12Th Floor Manyata Embassy Business Park Rachenahalli Outer Ring Road, Bangalore, Karnataka, India – 560045
  • Industry
    Pharma, Drug Formulation & Development
Company report
Astrazeneca Pharma India Limited - full intelligence report
  • Historical Financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Litigation, compliance and MCA filings
  • PDF report delivered after checkout
₹799 ₹999 20% off
Secure checkout · GST invoice included

Unlock the full Astrazeneca Pharma India Limited report

Financials, compliance, directors, charges, ownership and filings for Astrazeneca Pharma India Limited in one report.

10-year financials Directors & ownership Charges & compliance

CIN History of Astrazeneca Pharma India Limited

Astrazeneca Pharma India Limited has one previous CIN (Corporate Identification Number): L85110KA1979PLC003563. The current CIN is L24231KA1979PLC003563, which is the unique identifier assigned by the Registrar of Companies.

CIN Status
L24231KA1979PLC003563 Current
L85110KA1979PLC003563 Previous

Business Activity of Astrazeneca Pharma India Limited

Astrazeneca Pharma India Limited is engaged in the principal business activity of manufacturing, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.

Main Activity Group Code Description of Main Activity Business Activity Code Description of Business Activity Turnover Percentage
C Manufacturing C6 Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products *********

Auditor Details of Astrazeneca Pharma India Limited

Astrazeneca Pharma India Limited is audited by Price Waterhouse & Co Chartered Accountants LLP (ICAI peer reviewed, certificate valid till 2026-11-30) for the financial year 2026, as reported in its NSE exchange filings. The statutory auditor is responsible for expressing an independent opinion on whether the financial statements present a true and fair view in accordance with applicable accounting standards.

Name Financial year Audit opinion
Price Waterhouse & Co Chartered Accountants LLP (ICAI peer reviewed, certificate valid till 2026-11-30) FY 2026 Declaration of unmodified opinion

Board of Directors of Astrazeneca Pharma India Limited

Astrazeneca Pharma India Limited is currently managed by 9 directors, with 40 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.

Current Directors
Name Designation Appointment Date Tenure Status
Revathy Ashok
Also directs: Strategygarage Solutions Llp, Astrazeneca Pharma India Limited, Sansera Engineering Limited and 5 more
Director 02 Dec 2016 9 Years 7 Months Current
Hooi Bien Chuah
Also directs: Astrazeneca Pharma India Limited
Director 09 Nov 2023 2 Years 8 Months Current
Bhavana Agrawal
Also directs: Astrazeneca Pharma India Limited
Cfo 01 Oct 2023 2 Years 9 Months Current
Sylvia Lorena Varela Ramon
Also directs: Astrazeneca Pharma India Limited
Director 21 Dec 2023 2 Years 6 Months Current
Jesus Javier Diaz Ropero Esteso
Also directs: Astrazeneca Pharma India Limited
Director 13 Nov 2024 1 Years 7 Months Current
Monica Widhani
Also directs: Astrazeneca Pharma India Limited, H.G. Infra Engineering Limited (Part Ix), Dreamfolks Services Limited and 1 more
Director 25 Sep 2024 1 Years 9 Months Current
Showing 6 of 9 current directors. View all directors

Financials of Astrazeneca Pharma India Limited FY 2026 filings available

Astrazeneca Pharma India Limited reported revenue of ₹2,275.58 Cr (up 32.59% YoY) for FY 2026. Profit growth despite declining revenue indicates effective cost management and margin discipline.

Revenue · FY 2026
₹2,275.58 Cr ▲ 32.59%
Profit · FY 2026
₹187.52 Cr ▲ 62.02%
EBITDA · FY 2026
₹290.52 Cr ▼ 1.38%
Revenue₹ Cr · Standalone01,0002,0003,000FY 2020: ₹832 Cr832FY 2020FY 2021: ₹814 Cr · -2.2% YoY814-2.2%FY 2021FY 2022: ₹806 Cr · -1% YoY806-1%FY 2022FY 2023: ₹1,003 Cr · +24.5% YoY1,003+24.5%FY 2023FY 2024: ₹1,296 Cr · +29.2% YoY1,296+29.2%FY 2024FY 2025: ₹1,716 Cr · +32.5% YoY1,716+32.5%FY 2025FY 2026: ₹2,276 Cr · +32.6% YoY2,276+32.6%FY 2026
Net Profit₹ Cr · Standalone0100200FY 2020: ₹72 Cr72.2FY 2020FY 2021: ₹93 Cr · +29.2% YoY93.3+29.2%FY 2021FY 2022: ₹62 Cr · -34% YoY61.6-34%FY 2022FY 2023: ₹99 Cr · +61.2% YoY99.3+61.2%FY 2023FY 2024: ₹162 Cr · +62.7% YoY162+62.7%FY 2024FY 2025: ₹116 Cr · -28.3% YoY116-28.3%FY 2025FY 2026: ₹188 Cr · +62% YoY188+62%FY 2026
Quarterly Revenue₹ Cr · vs same quarter last year0250500750Q1'25: ₹388 Cr · +31.2% YoY388+31.2%Q1'25Q2'25: ₹408 Cr · +31.2% YoY408+31.2%Q2'25Q3'25: ₹440 Cr · +44% YoY440+44%Q3'25Q4'25: ₹480 Cr · +25.4% YoY480+25.4%Q4'25Q1'26: ₹526 Cr · +35.8% YoY526+35.8%Q1'26Q2'26: ₹559 Cr · +37% YoY559+37%Q2'26Q3'26: ₹612 Cr · +38.9% YoY612+38.9%Q3'26Q4'26: ₹579 Cr · +20.4% YoY579+20.4%Q4'26
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Revenue from Operations ₹2,275.58 Cr ₹1,716.29 Cr ₹1,295.53 Cr ₹1,002.97 Cr ₹805.6 Cr ₹813.56 Cr ₹831.81 Cr
Other Income ₹28.49 Cr ₹40.63 Cr ₹34.8 Cr ₹26.1 Cr ₹14.76 Cr ₹12.84 Cr ₹12.99 Cr
Total Income ₹2,304.07 Cr ₹1,756.92 Cr ₹1,330.33 Cr ₹1,029.07 Cr ₹820.36 Cr ₹826.41 Cr ₹844.8 Cr
Cost of Materials Consumed ₹9.49 Cr ₹287.13 Cr ₹129.02 Cr ₹84.38 Cr ₹89.61 Cr ₹97.26 Cr ₹70.21 Cr
Purchases of Stock-in-Trade ₹1,859.42 Cr ₹1,008.82 Cr ₹499.31 Cr ₹324.46 Cr ₹207.88 Cr ₹194.74 Cr ₹274.23 Cr
Changes in Inventories -₹488.37 Cr -₹332.94 Cr -₹33.77 Cr -₹48.86 Cr ₹14.47 Cr ₹2.95 Cr -₹39.21 Cr
Employee Benefit Expense ₹264.38 Cr ₹257.44 Cr ₹241.45 Cr ₹259.1 Cr ₹230.21 Cr ₹219.54 Cr ₹216.7 Cr
Finance Costs ₹4.49 Cr ₹1.46 Cr ₹1.2 Cr ₹63.32 Lakh ₹94.72 Lakh ₹1.09 Cr ₹1.14 Cr
Depreciation & Amortisation ₹28.58 Cr ₹39.99 Cr ₹14.94 Cr ₹16.26 Cr ₹16.95 Cr ₹20.13 Cr ₹18.58 Cr
Other Expenses ₹368.63 Cr ₹241.87 Cr ₹275.07 Cr ₹218.77 Cr ₹177.26 Cr ₹163.6 Cr ₹189.18 Cr
Total Expenses ₹2,046.62 Cr ₹1,503.77 Cr ₹1,127.22 Cr ₹854.74 Cr ₹737.32 Cr ₹699.31 Cr ₹730.84 Cr
Profit Before Exceptional Items & Tax ₹257.45 Cr ₹253.15 Cr ₹203.11 Cr ₹174.33 Cr ₹83.04 Cr ₹127.09 Cr ₹113.96 Cr
Exceptional Items -₹5.25 Cr -₹96.79 Cr ₹16.43 Cr -₹40.23 Cr ₹0 ₹0 ₹0
Profit Before Tax ₹252.2 Cr ₹156.36 Cr ₹219.54 Cr ₹134.1 Cr ₹83.04 Cr ₹127.09 Cr ₹113.96 Cr
Total Tax Expense ₹64.68 Cr ₹40.62 Cr ₹58.03 Cr ₹34.81 Cr ₹21.44 Cr ₹33.79 Cr ₹41.75 Cr
Net Profit ₹187.52 Cr ₹115.74 Cr ₹161.51 Cr ₹99.29 Cr ₹61.59 Cr ₹93.3 Cr ₹72.21 Cr
Other Comprehensive Income -₹4.44 Cr -₹1.17 Cr ₹1 Cr -₹2.61 Cr -₹1.73 Cr ₹3.43 Cr -₹4.92 Cr
Total Comprehensive Income ₹183.08 Cr ₹114.57 Cr ₹162.51 Cr ₹96.68 Cr ₹59.86 Cr ₹96.73 Cr ₹67.29 Cr
EBITDA (computed) ₹290.52 Cr ₹294.6 Cr ₹219.25 Cr ₹191.23 Cr ₹100.93 Cr ₹148.31 Cr ₹133.68 Cr
Basic EPS ₹75.01 ₹46.30 ₹64.60 ₹39.72 ₹24.64 ₹37.32 ₹28.88
Diluted EPS ₹0.00 ₹46.30 ₹64.60 ₹39.72 ₹24.64 ₹37.32 ₹28.88
Metrics FY 2026 FY 2025 FY 2024 FY 2023
Total Assets ₹1,989.1 Cr ₹1,518.12 Cr ₹1,078.03 Cr ₹984.89 Cr
Non-current Assets ₹249.17 Cr ₹175.77 Cr ₹145.32 Cr ₹97.83 Cr
Current Assets ₹1,732.19 Cr ₹1,342.35 Cr ₹932.71 Cr ₹887.06 Cr
Property, Plant & Equipment ₹117.47 Cr ₹63.58 Cr ₹60.37 Cr ₹68.86 Cr
Inventories ₹1,027.33 Cr ₹548.5 Cr ₹227.88 Cr ₹190.21 Cr
Trade Receivables ₹213.68 Cr ₹184.88 Cr ₹153.13 Cr ₹107.52 Cr
Cash & Equivalents ₹447.72 Cr ₹536.14 Cr ₹505.57 Cr ₹500.34 Cr
Equity (Net Worth) ₹872.79 Cr ₹770.35 Cr ₹711.92 Cr ₹588.69 Cr
Equity Share Capital ₹5 Cr ₹5 Cr ₹5 Cr ₹5 Cr
Borrowings (Non-current) ₹0 ₹0 ₹0 ₹0
Borrowings (Current) ₹0 ₹0 ₹0 ₹0
Total Debt (computed) ₹0 ₹0 ₹0 ₹0
Current Liabilities ₹981.81 Cr ₹703 Cr ₹357.12 Cr ₹383.94 Cr
Total Liabilities ₹1,116.31 Cr ₹747.77 Cr ₹366.11 Cr ₹396.2 Cr
The balance sheet became part of the exchange results-filing format in FY2023 - earlier years were not filed and are hidden.
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022
Operating Cash Flow -₹15.14 Cr ₹65.36 Cr ₹92.53 Cr ₹58.3 Cr ₹100.79 Cr
Investing Cash Flow ₹18.69 Cr ₹30.8 Cr ₹21.74 Cr ₹18.11 Cr ₹4.74 Cr
Financing Cash Flow -₹91.97 Cr -₹65.59 Cr -₹44.37 Cr -₹24.48 Cr -₹9.46 Cr
Capital Expenditure ₹3.61 Cr ₹1.75 Cr ₹10.76 Cr ₹8.52 Cr ₹9.62 Cr
Free Cash Flow (computed) -₹18.75 Cr ₹63.61 Cr ₹81.76 Cr ₹49.78 Cr ₹91.17 Cr
Dividends Paid ₹80 Cr ₹60 Cr ₹40 Cr ₹20 Cr ₹5 Cr
Net Change in Cash -₹88.42 Cr ₹30.57 Cr ₹69.9 Cr ₹51.92 Cr ₹96.08 Cr
The cash-flow statement became part of the exchange results-filing format in FY2022 - earlier years were not filed and are hidden.
Metrics Q4 FY26 Q3 FY26 Q2 FY26 Q1 FY26 Q4 FY25 Q3 FY25 Q2 FY25 Q1 FY25 Q4 FY24 Q3 FY24 Q2 FY24 Q1 FY24
Revenue from Operations ₹578.61 Cr ₹611.57 Cr ₹559.09 Cr ₹526.31 Cr ₹480.48 Cr ₹440.29 Cr ₹408 Cr ₹387.52 Cr ₹383.2 Cr ₹305.79 Cr ₹311.07 Cr ₹295.47 Cr
Other Income ₹5.95 Cr ₹5.13 Cr ₹6.17 Cr ₹11.24 Cr ₹16.15 Cr ₹7.98 Cr ₹8.15 Cr ₹8.35 Cr ₹8.66 Cr ₹9.66 Cr ₹8.37 Cr ₹8.1 Cr
Total Income ₹584.56 Cr ₹616.7 Cr ₹565.26 Cr ₹537.55 Cr ₹496.63 Cr ₹448.27 Cr ₹416.15 Cr ₹395.87 Cr ₹391.86 Cr ₹315.45 Cr ₹319.44 Cr ₹303.57 Cr
Cost of Materials Consumed ₹0 ₹0 ₹0 ₹9.49 Cr ₹94.25 Cr ₹69.88 Cr ₹77.15 Cr ₹45.85 Cr ₹33.62 Cr ₹37.52 Cr ₹38.8 Cr ₹19.08 Cr
Purchases of Stock-in-Trade ₹312.31 Cr ₹697.12 Cr ₹432.4 Cr ₹417.59 Cr ₹287.86 Cr ₹228.76 Cr ₹251.87 Cr ₹240.33 Cr ₹74.98 Cr ₹181.53 Cr ₹139.94 Cr ₹102.85 Cr
Changes in Inventories ₹81.94 Cr -₹330.73 Cr -₹107.91 Cr -₹131.67 Cr -₹122.5 Cr -₹51.61 Cr -₹103.09 Cr -₹55.74 Cr ₹104.95 Cr -₹70.76 Cr -₹56.62 Cr -₹11.34 Cr
Employee Benefit Expense ₹45.7 Cr ₹93.78 Cr ₹60.45 Cr ₹64.45 Cr ₹66.07 Cr ₹62.37 Cr ₹68.04 Cr ₹60.96 Cr ₹57.98 Cr ₹63.23 Cr ₹65.27 Cr ₹54.97 Cr
Finance Costs ₹2.04 Cr ₹1.06 Cr ₹67 Lakh ₹72 Lakh ₹68 Lakh ₹32.8 Lakh ₹34.4 Lakh ₹10.92 Lakh -₹6.56 Lakh ₹61.27 Lakh ₹50.01 Lakh ₹15.35 Lakh
Depreciation & Amortisation ₹5.6 Cr ₹3.84 Cr ₹2.57 Cr ₹16.57 Cr ₹17.69 Cr ₹9.07 Cr ₹9.32 Cr ₹3.91 Cr ₹3.76 Cr ₹3.7 Cr ₹3.67 Cr ₹3.8 Cr
Other Expenses ₹77.75 Cr ₹106.57 Cr ₹98.97 Cr ₹85.34 Cr ₹68.43 Cr ₹53.9 Cr ₹61.48 Cr ₹58.04 Cr ₹62.28 Cr ₹79.21 Cr ₹70.92 Cr ₹62.66 Cr
Total Expenses ₹525.34 Cr ₹571.64 Cr ₹487.15 Cr ₹462.49 Cr ₹412.48 Cr ₹372.7 Cr ₹365.12 Cr ₹353.46 Cr ₹337.51 Cr ₹295.05 Cr ₹262.49 Cr ₹232.17 Cr
Profit Before Exceptional Items & Tax ₹59.22 Cr ₹45.06 Cr ₹78.11 Cr ₹75.06 Cr ₹84.15 Cr ₹75.57 Cr ₹51.03 Cr ₹42.41 Cr ₹54.35 Cr ₹20.4 Cr ₹56.96 Cr ₹71.4 Cr
Exceptional Items -₹1.08 Cr ₹1.48 Cr -₹5.29 Cr -₹36 Lakh -₹5.68 Cr -₹33.55 Cr ₹0 -₹57.56 Cr ₹0 ₹0 ₹16.43 Cr ₹0
Profit Before Tax ₹58.14 Cr ₹46.54 Cr ₹72.82 Cr ₹74.7 Cr ₹78.47 Cr ₹42.02 Cr ₹51.03 Cr -₹15.16 Cr ₹54.35 Cr ₹20.4 Cr ₹73.38 Cr ₹71.4 Cr
Total Tax Expense ₹13.26 Cr ₹13.95 Cr ₹18.6 Cr ₹18.87 Cr ₹20.22 Cr ₹11.17 Cr ₹12.6 Cr -₹3.37 Cr ₹14.88 Cr ₹4.6 Cr ₹21.01 Cr ₹17.54 Cr
Net Profit ₹44.88 Cr ₹32.59 Cr ₹54.22 Cr ₹55.83 Cr ₹58.25 Cr ₹30.85 Cr ₹38.43 Cr -₹11.79 Cr ₹39.48 Cr ₹15.8 Cr ₹52.37 Cr ₹53.86 Cr
Other Comprehensive Income -₹4.76 Cr ₹1 Lakh -₹30 Lakh ₹61 Lakh ₹1.46 Cr -₹1.72 Cr -₹1.65 Cr ₹74 Lakh ₹20.45 Lakh ₹5.31 Lakh ₹28.73 Lakh ₹45.51 Lakh
Total Comprehensive Income ₹40.12 Cr ₹32.6 Cr ₹53.92 Cr ₹56.44 Cr ₹59.71 Cr ₹29.13 Cr ₹36.78 Cr -₹11.05 Cr ₹39.68 Cr ₹15.85 Cr ₹52.66 Cr ₹54.32 Cr
EBITDA (computed) ₹66.86 Cr ₹49.96 Cr ₹81.35 Cr ₹92.35 Cr ₹102.52 Cr ₹84.97 Cr ₹60.69 Cr ₹46.43 Cr ₹58.05 Cr ₹24.72 Cr ₹61.13 Cr ₹75.35 Cr
Basic EPS ₹17.95 ₹13.04 ₹21.69 ₹22.33 ₹23.30 ₹12.34 ₹15.37 ₹-4.72 ₹15.79 ₹6.32 ₹20.95 ₹21.54
Diluted EPS ₹0.00 ₹13.04 ₹21.69 ₹22.33 ₹23.30 ₹12.34 ₹15.37 ₹-4.72 ₹15.79 ₹6.32 ₹20.95 ₹21.54
Latest 12 quarters shown of 25 on record.
Want more history and ratios?
You're viewing the latest exchange-filed financials for Astrazeneca Pharma India Limited. The full report adds 10+ years of line-item history, 20+ ratios, peer benchmarks and a downloadable PDF.
10+ years of history 20+ ratios & benchmarks Downloadable PDF

Shareholding Pattern of Astrazeneca Pharma India Limited

As per the shareholding pattern filed with NSE for the quarter ended Mar 2026, promoters hold 75.00%, foreign institutional investors hold 2.78%, domestic institutional investors hold 5.80%, retail and other public shareholders hold 16.42% of Astrazeneca Pharma India Limited. The company had 29,007 shareholders on record.

Promoters: 75.00%DII (Domestic Institutional): 5.80%FII (Foreign Institutional): 2.78%Retail & Others: 16.42%
Mar 2026
QUARTER
75.00% Promoters
5.80% DII (Domestic Institutional)
2.78% FII (Foreign Institutional)
16.42% Retail & Others
Promoter holding - history
Now 75.00% · Mar 2026High 75.00% · Dec 2015Low 75.00% · Dec 2015
74%74.5%75%75.5%76%Dec 2015Jun 2018Dec 2020Jun 2023Dec 2025Dec 2015: 75.00%Mar 2016: 75.00%Jun 2016: 75.00%Sep 2016: 75.00%Dec 2016: 75.00%Mar 2017: 75.00%Jun 2017: 75.00%Sep 2017: 75.00%Dec 2017: 75.00%Mar 2018: 75.00%Jun 2018: 75.00%Sep 2018: 75.00%Dec 2018: 75.00%Mar 2019: 75.00%Jun 2019: 75.00%Sep 2019: 75.00%Dec 2019: 75.00%Mar 2020: 75.00%Jun 2020: 75.00%Sep 2020: 75.00%Dec 2020: 75.00%Mar 2021: 75.00%Jun 2021: 75.00%Sep 2021: 75.00%Dec 2021: 75.00%Mar 2022: 75.00%Jun 2022: 75.00%Sep 2022: 75.00%Dec 2022: 75.00%Mar 2023: 75.00%Jun 2023: 75.00%Sep 2023: 75.00%Dec 2023: 75.00%Mar 2024: 75.00%Jun 2024: 75.00%Sep 2024: 75.00%Dec 2024: 75.00%Mar 2025: 75.00%Jun 2025: 75.00%Sep 2025: 75.00%Dec 2025: 75.00%Mar 2026: 75.00%75.00%75.00%
Shareholding trend - last 6 quarters
Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Promoters75.00%75.00%75.00%75.00%75.00%75.00%
Public25.00%25.00%25.00%25.00%25.00%25.00%
Shareholding history - year on year (as at 31 March)
Mar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018Mar 2017Mar 2016
Promoters75.00%75.00%75.00%75.00%75.00%75.00%75.00%75.00%75.00%75.00%75.00%
Public25.00%25.00%25.00%25.00%25.00%25.00%25.00%25.00%25.00%25.00%25.00%
Promoter change (YoY, %pts)+0.00+0.00+0.00+0.00+0.00+0.00+0.00+0.00+0.00+0.00-

Board & Governance of Astrazeneca Pharma India Limited

As per the corporate governance filing with NSE for the quarter ended 31-DEC-2025, the board of Astrazeneca Pharma India Limited has 8 directors - 3 independent and 2 executive. The board is chaired by SHILPA DIVEKAR NIRULA.

DirectorPositionOn board sinceListed boards
SHILPA DIVEKAR NIRULA Non-Executive - Independent Director · Chairperson 2021-12-29 2
REVATHY ASHOK Non-Executive - Independent Director 2016-12-02 5
MONICA WIDHANI Non-Executive - Independent Director 2024-09-25 5
PRAVEEN RAO AKKINEPALLY Executive Director 2025-07-01 1
JESUS JAVIER DIAZ-ROPERO ESTESO Non-Executive - Non Independent Director 2024-11-13 1
SYLVIA LORENA VARELA RAMON Non-Executive - Non Independent Director 2023-12-21 1
HOOI BIEN CHUAH Non-Executive - Non Independent Director 2023-11-09 1
BHAVANA AGRAWAL Executive Director 2024-02-08 1
Board Committees
CommitteeMembers
Audit Committee MONICA WIDHANI (Chairperson), SHILPA DIVEKAR NIRULA, REVATHY ASHOK, HOOI BIEN CHUAH
Nomination and remuneration committee REVATHY ASHOK (Chairperson), SHILPA DIVEKAR NIRULA, SYLVIA LORENA VARELA RAMON
Stakeholders Relationship Committee SYLVIA LORENA VARELA RAMON (Chairperson), SHILPA DIVEKAR NIRULA, SHILPA DIVEKAR NIRULA, PRAVEEN RAO AKKINEPALLY, BHAVANA AGRAWAL
Risk Management Committee MONICA WIDHANI (Chairperson), PRAVEEN RAO AKKINEPALLY, BHAVANA AGRAWAL, SRIKANTH B S, AMARPREET KAUR AHUJA
Corporate Social Responsibility Committee HOOI BIEN CHUAH (Chairperson), REVATHY ASHOK, PRAVEEN RAO AKKINEPALLY

Charges & Borrowings of Astrazeneca Pharma India Limited

Open charges
₹0
Satisfied charges
₹62.5 Cr
Breakdown by lending institutions
Il & Fs Trust Company Limited₹62.50 Cr
Latest charge details
DateLenderAmountStatus
16 Jan 2008 Il & Fs Trust Company Limited ₹62.5 Cr Satisfied

Total charge records: 1 View all charges

Employees and EPFO Compliance at Astrazeneca Pharma India Limited

Astrazeneca Pharma India Limited has a workforce of 935 employees as of Apr 07, 2024.

Employee count
935
Active EPFO establishments
2
Employee growth
-13.59%
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026

Employee Count & EPFO Data of Astrazeneca Pharma India Limited

Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.

Monthly employee headcount & PF contributions
EPFO establishment details & ECR filing status
Year-wise workforce analytics & attrition trends
PF exemption, coverage & compliance verification

GST Compliance of Astrazeneca Pharma India Limited

XX%
Compliant
GSTR-1
GSTR-3B
GSTR-9
MH
KA
UP
TN
TS

GSTIN & GST Filing Data of Astrazeneca Pharma India Limited

Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.

GSTIN registrations & state-wise presence
Filing compliance - GSTR-1, GSTR-3B, GSTR-9
HSN/SAC codes with goods & services details
Taxpayer type, jurisdiction & business constitution

Credit Ratings, Litigation & Regulatory Alerts for Astrazeneca Pharma India Limited

Credit rating
AAA
AA+
AA
AA-
! !
2015 2017 2019 2021 2023
Litigation
District Court 35
High Court 45
Supreme Court 0
NCLT / NCLAT 0
Pending
Disposed
Regulatory alerts
GSTIN Cancelled
Andhra Pradesh
GSTIN Cancelled
Telangana (on application)
EPFO Delay
12 months delay - Haryana
Violations via Directors
20 MCA + 19 Bank defaults

Credit Ratings, Legal Cases & Regulatory Alerts of Astrazeneca Pharma India Limited

Access complete credit rating history, litigation records, regulatory alerts, and compliance data.

Credit rating history across CARE, ICRA, Brickwork & India Ratings
Instrument-wise ratings, outlook & action timeline
Court-wise litigation (District, High Court, Supreme Court, NCLT)
Group company & common directorship litigation
Statutory compliance alerts (GSTIN, EPFO, ROC)
Director & company violations (MCA, SEBI, Banks, BSE/NSE)

MSME Payment Delays by Astrazeneca Pharma India Limited

MSME Payment Delays by Astrazeneca Pharma India Limited

Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.

Amounts outstanding to MSME suppliers
Delay periods & reasons for delayed payments
Half-yearly MSME-1 filing history
Vendor-payment behaviour as a counterparty risk signal

Subsidiaries & Group Companies of Astrazeneca Pharma India Limited

Subsidiaries & Group Companies of Astrazeneca Pharma India Limited

See the full corporate group - holding company, subsidiaries, associates and joint ventures of Astrazeneca Pharma India Limited with ownership details.

Holding & parent company details
Subsidiaries & step-down subsidiaries with % holding
Associates & joint ventures with partner details
Investments in other entities year-on-year

MCA Filings & Documents of Astrazeneca Pharma India Limited

MCA Filings & Documents of Astrazeneca Pharma India Limited

Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.

Incorporation documents, MoA & AoA
Annual returns (MGT-7) & financial statements (AOC-4)
Charge filings (CHG-1, CHG-4) & resolutions
Complete document index with filing dates

Recent Activity on Astrazeneca Pharma India Limited

Activity
14 Aug 2025
Astrazeneca Pharma India Limited last Annual general meeting of members was held on 14 Aug 2025 as per latest MCA records.
Directors
01 Jul 2025
Praveen Rao Akkinepally was appointed as a Managing Director on 01 Jul 2025 & has been associated with this company since 1 year 8 days.
Activity
31 Mar 2025
Astrazeneca Pharma India Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Bangalore.
Directors
13 Nov 2024
Jesus Javier Diaz Ropero Esteso was appointed as a Director on 13 Nov 2024 & has been associated with this company since 1 year 7 months.
Directors
25 Sep 2024
Monica Widhani was appointed as a Director on 25 Sep 2024 & has been associated with this company since 1 year 9 months.
Directors
15 Mar 2024
Bhavana Agrawal was appointed as a CFO on 15 Mar 2024 & has been associated with this company since 2 years 3 months.

Recent News on Astrazeneca Pharma India Limited

Aliaxis welcomes Jeyamalini Natesan as CHRO
11 Dec 2023 · People Matters
Eugia Pharma gets USFDA nod for Budesonide generic
30 Nov 2023 · Thehindubusinessline

Frequently Asked Questions about Astrazeneca Pharma India Limited

Astrazeneca Pharma India Limited is an active public limited company in the pharma sector based in Bangalore, Karnataka, India. It was incorporated on 11 July 1979 (47+ years old) and is registered under CIN L24231KA1979PLC003563. Listed on BSE: 506820 and NSE: ASTRAZEN. The company has 935 employees.

Astrazeneca Pharma India Limited reported revenue of ₹1,756.92 Cr for FY 2025 (up 32.00% YoY).

The current directors of Astrazeneca Pharma India Limited are:

The primary industry of Astrazeneca Pharma India Limited is pharma. The company specifically operates in drug formulation and development. The company is currently active in this sector.

Yes. Astrazeneca Pharma India Limited is listed on both BSE (code: 506820) and NSE (symbol: ASTRAZEN).

Astrazeneca Pharma India Limited can be reached at the registered office: Block N1 12Th Floor Manyata Embassy Business Park Rachenahalli Outer Ring Road, Bangalore, Karnataka, India – 560045, or through the website astrazeneca.in.

7M+ Indian companies. One platform.

Financials, directors, compliance, charges and shareholding - sourced from MCA, SEBI and RBI filings.

Subscription plans available